Boehringer takes up option for Oxford Biomedica CF drug

German family-owned pharma major Boehringer Ingelheim today said it has exercised its option to license UK-based Oxford Biomedica’s (LSE: OXB) lentiviral vector technology to manufacture, register and commercialize BI 3720931, a lentiviral vector-based gene therapy for the treatment of cystic fibrosis (CF).

Under the terms of the option and license agreement with Boehringer Ingelheim, originally announced in  August 2018, Boehringer Ingelheim will pay Oxford Biomedica an option exercise fee of £3.5 million. The British firm is further entitled to development, regulatory and sales milestones of up to a further £27.5 million, in addition to a tiered low single digit royalty on net sales of a CF gene therapy product. This option exercise by Boehringer Ingelheim follows on another recent signature of a Development & Supply Agreement which was announced in April 2021, relating to the clinical manufacture of various types of viral vector-based products.

And deal with Cystic Fibrosis Gene Therapy Consortium